Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec 15;6(4):46.
doi: 10.3390/metabo6040046.

Current and Future Perspectives on the Structural Identification of Small Molecules in Biological Systems

Affiliations
Review

Current and Future Perspectives on the Structural Identification of Small Molecules in Biological Systems

Daniel A Dias et al. Metabolites. .

Abstract

Although significant advances have been made in recent years, the structural elucidation of small molecules continues to remain a challenging issue for metabolite profiling. Many metabolomic studies feature unknown compounds; sometimes even in the list of features identified as "statistically significant" in the study. Such metabolic "dark matter" means that much of the potential information collected by metabolomics studies is lost. Accurate structure elucidation allows researchers to identify these compounds. This in turn, facilitates downstream metabolite pathway analysis, and a better understanding of the underlying biology of the system under investigation. This review covers a range of methods for the structural elucidation of individual compounds, including those based on gas and liquid chromatography hyphenated to mass spectrometry, single and multi-dimensional nuclear magnetic resonance spectroscopy, and high-resolution mass spectrometry and includes discussion of data standardization. Future perspectives in structure elucidation are also discussed; with a focus on the potential development of instruments and techniques, in both nuclear magnetic resonance spectroscopy and mass spectrometry that, may help solve some of the current issues that are hampering the complete identification of metabolite structure and function.

Keywords: Fourier transform-infrared spectroscopy; mass spectrometry; metabolite profiling; metabolomics; nuclear magnetic resonance spectroscopy; structure elucidation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Nuclear magnetic resonance spectroscopy (NMR) of aqueous metabolites extracted from a sample of Daphnia magna. Complex overlapping peaks can be observed even in a shift range of just 0.5–5 ppm.
Figure 2
Figure 2
Section of a 1H NMR of soil extract (black) overlaid with NMR spectra of lactate (red) and valine (blue).
Figure 3
Figure 3
2D COSY 1H spectra of the Daphia sample from Figure 1 illustrating cross peaks.
Figure 4
Figure 4
Identification of molecular formula using uHRMS in combination with isotopic fine structure: (A) Full Scan MS+ spectra for a glutathione standard showing three calculated formula matches within 2 ppm mass error; (B) Expansion of m/z 309.07–309.13 showing M + 1 isotopologues and inability to determine parent formula; (C) Expansion of m/z 310.06–310.13 showing M + 2 isotopologues with calculated isotopic fine structure match of 34S, 18O and 13C2 isotopologues to C10H17N3O6S matching the glutathione standard, other formula fine structures do not match the same isotopologue profile.
Figure 5
Figure 5
Dereplication and identification strategy using Liquid Chromatography Mass Spectrometry: (A) Reverse Phase ESI+ Total Ion Chromatogram with overlaid Extracted Molecular Features of Canola Extract; (B) Extracted Ion Chromatogram of the molecular formula corresponding to the plant hormone methyl jasmonate with inlaid Find-by-Formula Spectrum showing observed and predicted isotopic abundance for the feature at 9.880–9.965 min; (C) Product Ion spectra of methyl jasmonate using collision voltage of 20.0 eV; (D) Spectral match of methyl jasmonate MS/MS spectra to the METLIN Database allowing Putative identification.
Figure 6
Figure 6
Comparison between the FTIR Response Spectra of E. coli and L. innocua at the surfactants concentrations of N-tetradecyltropinium bromide that resulted in 100% mortality. Note: a.u. stands for “arbitrary units”. Arrows correspond to the wavenumbers referred to peptidoglycan while circles to the wavenumbers referred to the major response peaks in each species. Blue, L. innocua; Red, E. coli. The synthetic stress of the metabolomic stress response are defined by the following FTIR regions: fatty acids (W1) from 3000 to 2800 cm−1, amides (W2) from 1800 to 1500 cm−1, mixed region (W3) from 1500 to 1200 cm−1, carbohydrates (W4) from 1200 to 900 cm−1 and typing region (W5) from 900 to 700 cm−1. Adapted from Corte et al. [125].

References

    1. Katz L., Baltz R.H. Natural product discovery: Past, present, and future. J. Ind. Microbiol. Biotechnol. 2016;43:155–176. doi: 10.1007/s10295-015-1723-5. - DOI - PubMed
    1. David B., Wolfender J.-L., Dias D.A. The pharmaceutical industry and natural products: Historical status and new trends. Phytochem. Rev. 2015;14:299–315. doi: 10.1007/s11101-014-9367-z. - DOI
    1. Lia D., Misialek J.R., Boerwinkle E., Gottesman R.F., Sharrette A.R., Mosley T.H., Coresh J., Wruck L.M., Knopman D.S., Alonso A. Plasma phospholipids and prevalence of mild cognitive impairment and/or dementia in the aric neurocognitive study (ARIC-NCS) Alzheimer Dement. Diagn. Assess. Dis. Monit. 2016;3:73–82. doi: 10.1016/j.dadm.2016.02.008. - DOI - PMC - PubMed
    1. González-Domínguez R., Rupérez F.J., García-Barrera T., Barbas C., Gómez-Ariza J.L. Metabolomic-driven elucidation of serum disturbances associated with Alzheimer’s disease and mild cognitive impairment. Curr. Alzheimer Res. 2016;13:641–653. doi: 10.2174/1567205013666160129095138. - DOI - PubMed
    1. Fiandaca M.S., Zhong X., Cheema A.K., Orquiza M.H., Chidambaram S., Tan M.T., Gresenz C.R., FitzGerald K.T., Nalls M.A., Singleton A.B., et al. Plasma 24-metabolite panel predicts preclinical transition to clinical stages of Alzheimer’s disease. Front. Neurol. 2015;12:237. doi: 10.3389/fneur.2015.00237. - DOI - PMC - PubMed